MMPs, TIMP-2, AND TGF-β1 in the cancerization of oral lichen planus

Head and Neck

Volumn 30, Issue 9, 2008, Pages 1237-1245

  Chen, Yu ^a   Zhang, Weiping ^b   Geng, Ning ^a   Tian, Kun ^a   Windsor, Lester Jack ^b  

^a SICHUAN UNIVERSITY   (China)

^b INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

Author keywords

Matrix metalloproteinases; Oral lichen planus; Squamous cell carcinoma; Tissue inhibitor of matrix metalloproteinases; Transforming growth factor l

Indexed keywords

MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; ATROPHIC SKIN DISEASE; CARCINOGENESIS; CLINICAL FEATURE; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LICHEN PLANUS; MALE; MUCOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGE FACTORS; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LICHEN PLANUS, ORAL; MALE; METALLOPROTEASES; MIDDLE AGED; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; PROBABILITY; PROGNOSIS; REFERENCE VALUES; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 51949084445     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20869     Document Type: Article

References (35)

1. Bode W. Structural basis of matrix metalloproteinase function. Biochem Soc Symp 2003;70:1-14.
2. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, eg, acute leukemia. Crit Rev Oncol Hematol 2004;50:87-100.
3. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 2007;29:564-572.
4. Bindhu OS, Ramadas K, Sebastian P, Pillai MR. High expression levels of nuclear factor kappa B and gelatinases in the tumorigenesis of oral squamous cell carcinoma. Head Neck 2006;28:916-925.
5. Rosenthal EL, Matrisian LM. Matrix metalloproteases in head and neck cancer. Head Neck 2006;28:639-648.
6. Cai H-x, Pan C-b, Li H-g. Expression of matrix metalloproteinases in cancerization of oral mucosa. Acad J SUMS 2002;23:477-479.
7. Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW, Chang KW. Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med 2004;33:405-409.
8. Yu C, Zhou Y, Miao X, Xiong P, Tan W, Lin D. Functional haplotypes in the promoter of matrix metallopro-teinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res 2004;64:7622-7628.
9. Jordan RC, Macabeo-Ong M, Shiboski CH, et al Overexpression of matrix metalloproteinase-1 and -9 mRNA is associated with progression of oral dysplasia to cancer. Clin Cancer Res 2004;10:6460-6465.
10. Zhang WP, Chen Y, Geng N, Tian K, Bao DM, Yang MZ. The role of matrix metalloproteinases and their tissue inhibitors in oral lichen planus. Zhonghua Kou Qiang Yi Xue Za Zhi 2006;41:420-421.
11. Kurahara S, Shinohara M, Ikebe T, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1999;21:627-638.
12. Gorogh T, Beier UH, Baumken J, et al. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck 2006;28:31-39.
13. Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep 2004;6:96-102.
14. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-2392.
15. Chin D, Boyle GM, Parsons PG, Coman WB. What is transforming growth factor-beta (TGF-beta)? Br J Plast Surg 2004;57:215-221.
16. Kim IY, Kim MM, Kim SJ. Transforming growth factor-beta: biology and clinical relevance. J Biochem Mol Biol 2005;38:1-8.
17. Pasini FS, Brentani MM, Kowalski LP, Federico MH. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck 2001;23:725-732.
18. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005;23:2078-2093.
19. Munshi HG, Wu YI, Mukhopadhyay S, et al. Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-betal-induced pericellular collagenolysis. J Biol Chem 2004;279:39042-39050.
20. Salo T, Lyons JG, Rahemtulla F, Birkedal-Hansen H, Larjava H. Transforming growth factor-beta 1 up-regulates type IV collagenase expression in cultured human keratinocytes. J Biol Chem 1991;266:11436-11441.
21. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 1991;266:14064-14071.
22. Cawson RA, Odell EW. Cawson's essential of oral pathology and oral medicine. In: Cawson RA, Odell EW, editors. Disease of the oral mucosa: non-infective stomatitis, 7th ed. London: Churchill Livingstone; 2002. pp 197-201.
23. Dissemond J. Oral lichen planus: an overview. J Dermatolog Treat 2004;15:136-140.
24. Trgezi JA, Sciubba JJ, Jordan RC. Oral pathology: clinical pathologic correlation. In: Trgezi JA, Sciubba JJ, Jordan RC, editors. White lesions, 4th ed. St Louis Missouri: Saunders; 2003. pp 92-97.
25. Lee JJ, Kuo MY, Cheng SJ, et al. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen planus and patients with areca quid chewing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:471-478.
26. Nagel H, Laskawi R, Wahlers A, Hemmerlein B. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology 2004;44:222-231.
27. Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D. Immune enhancement of skin carci-nogenesis by CD4+ T cells. J Exp Med 2003;197:1017-1028.
28. Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2004;130:37-44.
29. Sugerman PB, Savage NW, Walsh LJ, et al. The patho-genesis of oral lichen planus. Crit Rev Oral Biol Med 2002;13:350-365.
30. Galateau-Salle FB, Luna RE, Horiba K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 2000;31:296-305.
31. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 2002;95:1902-1910.
32. Worley JR, Thompkins PB, Lee MH, et al. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP). Biochem J 2003;372:799-809.
33. Lu SL, Reh D, Li AG, et al. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 2004;64:4405-4410.
34. Rich J, Borton A, Wang X. Transforming growth factor-beta signaling in cancer. Microsc Res Tech 2001;52:363-373.
35. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001;23:147-159.